ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust®) Versus Herceptin® in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03425656
Recruitment Status : Recruiting
First Posted : February 7, 2018
Last Update Posted : February 7, 2018
Sponsor:
Information provided by (Responsible Party):
AryoGen Pharmed Co.

Brief Summary:
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust™ (Aryogen Trastuzumab in comparison to Herceptin® (Genentech/Roche) in patients with Human Epidermal Growth Factor Receptor 2-Positive breast cancer. The main objective is to verify the non-inferiority of AryoTrust™ (Aryogen trastuzumab) vs. Herceptin® (Genentech/Roche trastuzumab), both given concomitantly with docetaxel after doxorubicin plus cyclophosphamide in the neoadjuvant setting according to pathological complete response (pCR) as primary objective and objective response (cOR), clinical complete response (cCR), clinical partial response (cPR), clinically no change (cNC), clinical progressive disease (cPD), breast conservation rate as Secondary objectives of this study. Evaluating the safety and immunogenicity of AryoTrust™ vs. Herceptin®, are also the other secondary outcomes. This study has two arms and 108 subjects will participate with a 1:1 allocation and receive mentioned treatment randomly.

Condition or disease Intervention/treatment Phase
Malignant Neoplasm of Breast Drug: Trastuzumab plus docetaxel (for 4 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Two-armed, Patient-outcome Assessor-data Analyzer Blinded, Parallel Active Controlled Non-Inferiority Clinical Trial Study of AryoTrust™ (Aryogen Trastuzumab ) Efficacy and Safety in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Comparison to Herceptin® (Genentech/Roche) Control.
Actual Study Start Date : July 9, 2016
Estimated Primary Completion Date : October 30, 2018
Estimated Study Completion Date : October 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Trastuzumab (AryoTrust)
Trastuzumab (AryoTrust) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
Drug: Trastuzumab plus docetaxel (for 4 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
Trastuzumab (8 mg/kg IV loading doseat cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for 4 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)

Active Comparator: Trastuzumab (Herceptin)
Trastuzumab (Herceptin) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
Drug: Trastuzumab plus docetaxel (for 4 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
Trastuzumab (8 mg/kg IV loading doseat cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for 4 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)




Primary Outcome Measures :
  1. pathologic Complete Response [ Time Frame: week 24 ]
    the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes


Secondary Outcome Measures :
  1. clinical Complete Response [ Time Frame: week 23 ]
    Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm

  2. clinical Partial Response [ Time Frame: week 21 ]
    At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters

  3. clinically Stable Disease [ Time Frame: week 21 ]
    Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest diameters while on study

  4. clinical Progressive Disease [ Time Frame: within week 23 ]
    At least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)

  5. clinical Objective Response [ Time Frame: week 21 ]
    clinical Complete Response + clinical Partial Response

  6. Adverse event assessment [ Time Frame: up to week 26 ]
    Adverse event

  7. Immunogenicity [ Time Frame: week 0, week 3, week 9, week 15, week 26 ]
    antidrug antibody



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-65 years old female patients
  • Patients with newly diagnosed stage III (locally advanced) or in-operable stage II (due to sizes larger than 5 cm or high tumor to breast ratio) tumors are candidates for participation. (Appendix 1)
  • Willing and able to sign an informed consent
  • Pathological diagnosis of adenocarcinoma of the breast
  • ECOG status of 0-1
  • With any ER/PR status
  • HER2 positive (Immunohistochemical (IHC) 3+ intensity, amplification of the HER2 gene on fluorescence in situ hybridization (FISH+ ) or HER2 positive results of Chromogenic in situ hybridization (CISH)).

Exclusion Criteria:

  • Clinical or radiologic evidence of metastatic disease
  • History of any other malignancy including previous breast cancer, second non-breast malignant disease
  • History of previous chemotherapy
  • Left ventricular ejection fraction [LVEF] <55% confirmed by echo cardiogram within 3 months before registration, Any prior myocardial infarction, History of documented congestive heart failure (CHF),Any prior history of arrhythmia or cardiac valvular disease requiring medications or clinically significant, Current use of medications for treatment of angina pectoris, Current uncontrolled hypertension (diastolic > 100 mmHg or systolic > 200 mmHg), A severe conduction abnormality (having pacemaker or diagnosed by the ECG) and any other significant cardiovascular disease.
  • Hematologic abnormalities including baseline Absolute Neutrophil Count (ANC) of ≤1,500/µL or platelet count ≤ 100,000/µL
  • Liver dysfunction including : (baseline)

    • Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) ≥ 3 Upper Limit Normal (ULN)
    • Alkaline phosphatase (ALP) ≥3 ͯ ULN
    • serum total bilirubin > 1.5 ULN
  • Renal dysfunction, defined as serum creatinine ≥2.5 mg/dL
  • Pregnant, lactating women or women of childbearing potential who are not willing to use adequate contraception
  • Current Corneal abrasion and ulcer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03425656


Contacts
Contact: Somayeh Amini, Pharm D 00982143473000 amini.s@orchidpharmed.com

Locations
Iran, Islamic Republic of
Imam Khomeini hospital Recruiting
Tehran, Iran, Islamic Republic of
Contact: Morteza Azhdarzadeh, Pharm D    00982143473000    azhdarzadeh.m@orchidpharmed.com   
Sponsors and Collaborators
AryoGen Pharmed Co.

Responsible Party: AryoGen Pharmed Co.
ClinicalTrials.gov Identifier: NCT03425656     History of Changes
Other Study ID Numbers: TRA.ARY.RS.94 (III)
First Posted: February 7, 2018    Key Record Dates
Last Update Posted: February 7, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by AryoGen Pharmed Co.:
breast cancer
AryoTrust™
Herceptin®
non-Inferiority

Additional relevant MeSH terms:
Breast Diseases
Breast Neoplasms
Neoplasms
Neoplasms by Site
Skin Diseases
Cyclophosphamide
Docetaxel
Liposomal doxorubicin
Doxorubicin
Trastuzumab
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors